UK HealthCare logo

Practice areas

  • Carcinoid and Neuroendocrine Cancer Team
  • Endocrine Cancer Team
  • Medical Oncology

Faculty rank

Professor of Medicine

Clinic information

Clinical interests

  • Clinical Pharmacology
  • Clinical Trials
  • Gastrointestinal Cancer
  • Injectable Radiolabeled Compounds
  • Medical Oncology
  • Neuroendocrine Cancer



Vanderbilt University, School of Medicine, Nashville, Tenn.


Vanderbilt University, School of Medicine, Nashville, Tenn.


Medical Oncology and Clinical Pharmacology, Vanderbilt University, School of Medicine, Nashville, Tenn.

Certifications or Special training

American Board of Internal Medicine
American Board of Internal Medicine, Medical Oncology
Fellow of the American College of Physicians

Additional information


My name is Lowell Anthony; I joined the UK Markey Cancer Center with more than two decades of experience in oncology and a special focus in gastrointestinal and neuroendocrine oncology. My clinical interests include drug development ranging from Phase I to III clinical trials. Agents targeting specific cellular signaling pathways and injectable radiolabeled compounds make up my past and current clinical investigative interests. I bring a clinical correlative component to complement the ongoing translational activities at Markey Cancer Center.

I attended Vanderbilt University Medical School, where I also completed a medical residency and fellowship training in medical oncology and clinical pharmacology. I have previously been on the medical faculties at Vanderbilt University and the Louisiana State University Health Sciences Center in New Orleans.

Dr. Lowell Anthony and Geri McDowell patient storyDr. Lowell Anthony listens to Geri's heart during a followup visit. Read her story »

Personal statement

It takes a village to treat cancer, so when the patient is initially evaluated at Markey Cancer Center, a care plan is developed across specialties. So it's more encompassing than just a single visit to one specialist who treats cancer. Right now in oncology, the most exciting development is immunotherapy. Our challenge is to find out how we integrate this into other forms of how we treat cancer; both from other medicine, other drugs and potentially other modalities such as radiation.


  1. Saeed H, Hnoosh D, Huang B, Durbin EB, McGrath PC, Desimone P, Maynard E, Anthony LB, Dineen SP, Hosein PJ, Tzeng CD. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. J Surg Oncol. 2016 May 30.
    View in: PubMed
  2. Hilal T, Anthony LB, Sorrell VL. Unexpected Cardiac Masses. JAMA Oncol. 2015 Dec;1(9):1343-4.
    View in: PubMed
  3. Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, Hörsch D, Van Cutsem E, Öberg K, Yao JC. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial. Neuroendocrinology. 2015;102(1-2):18-25.
    View in: PubMed
  4. Anthony LB. Practical guide to supportive care of patients with functional neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):45-55. PMID: 23391112.
    View in: PubMed
  5. Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T, Anthony LB, Hobday T. Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study. Oncologist. 2013; 18(1):46-53. PMID: 23263288.
    View in: PubMed
  6. Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012 Oct; 19(5):657-66. PMID: 22807497.
    View in: PubMed
  7. Delpassand ES, Samarghandi A, Mourtada JS, Zamanian S, Espenan GD, Sharif R, Mackenzie S, Kosari K, Barakat O, Naqvi S, Seng JE, Anthony L. Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide. Theranostics. 2012; 2(5):472-80. PMID: 22737186.
    View in: PubMed
  8. Brashear J, Ryan P, Wang YZ, Anthony LB, Boudreaux JP, Joseph S, Campeau R, Woltering EA. A prospective evaluation of the value of intensive previsit counseling in patients with neuroendocrine tumors. Am Surg. 2012 Jan; 78(1):E43-4. PMID: 22273307.
    View in: PubMed
  9. Anthony L, Vinik AI. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas. 2011 Oct; 40(7):987-94. PMID: 21697761.
    View in: PubMed
  10. Ludlam WH, Anthony L. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther. 2011 Oct; 28(10):825-41. PMID: 21964965.
    View in: PubMed
  11. Hoff PM, Kopetz S, Thomas MB, Langleben A, Rinaldi D, Anthony L, Wolff RA, Lassere Y, Abbruzzese JL. A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer. 2008 Sep 2; 99(5):722-6. PMID: 18728662.
    View in: PubMed
  12. Delpassand ES, Sims-Mourtada J, Saso H, Azhdarinia A, Ashoori F, Torabi F, Espenan G, Moore WH, Woltering E, Anthony L. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm. 2008 Jun; 23(3):292-300. PMID: 18593362.
    View in: PubMed
  13. Maroun JA, Anthony LB, Blais N, Burkes R, Dowden SD, Dranitsaris G, Samson B, Shah A, Thirlwell MP, Vincent MD, Wong R. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol. 2007 Feb; 14(1):13-20. PMID: 17576459.
    View in: PubMed
  14. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002 Apr; 32(2):123-32. PMID: 11965607.
    View in: PubMed